Could a diabetes drug ease a rare heart condition?
NCT ID NCT06433050
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early study tests whether sotagliflozin, a drug already used for heart failure, can help people with a type of hypertrophic cardiomyopathy that doesn't block blood flow. Twenty-six adults will take the drug or a placebo for 12 weeks, then switch, to see if it improves exercise capacity and heart function. The goal is to find a new treatment option for this condition.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Sotagliflozin (a drug that blocks two sodium-glucose transporters, used for heart failure and diabetes)
- What this could lead to
- If it works, this could point toward a new treatment option for people with nonobstructive hypertrophic cardiomyopathy, potentially improving their exercise ability and heart function.
- What could go wrong
- This is a very early, small trial with only 26 participants, so results may not apply to everyone. The drug may not show clear benefits or could cause side effects like dehydration or urinary tract infections.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERTROPHIC CARDIOMYOPATHY WITHOUT OBSTRUCTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Pennsylvania
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.